AU2001287157A1 - Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents - Google Patents

Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents

Info

Publication number
AU2001287157A1
AU2001287157A1 AU2001287157A AU8715701A AU2001287157A1 AU 2001287157 A1 AU2001287157 A1 AU 2001287157A1 AU 2001287157 A AU2001287157 A AU 2001287157A AU 8715701 A AU8715701 A AU 8715701A AU 2001287157 A1 AU2001287157 A1 AU 2001287157A1
Authority
AU
Australia
Prior art keywords
adoptosis
promotion
administration
cancer cells
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287157A
Inventor
Leanne Cartee
Paul Dent
Steven Grant
Roberto Rosato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of AU2001287157A1 publication Critical patent/AU2001287157A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
AU2001287157A 2000-09-12 2001-09-07 Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents Abandoned AU2001287157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23188500P 2000-09-12 2000-09-12
US60231885 2000-09-12
PCT/US2001/028297 WO2002022133A1 (en) 2000-09-12 2001-09-07 Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents

Publications (1)

Publication Number Publication Date
AU2001287157A1 true AU2001287157A1 (en) 2002-03-26

Family

ID=22871001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287157A Abandoned AU2001287157A1 (en) 2000-09-12 2001-09-07 Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents

Country Status (3)

Country Link
US (1) US20050004007A1 (en)
AU (1) AU2001287157A1 (en)
WO (1) WO2002022133A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
PL414997A1 (en) * 2001-02-19 2016-02-29 Novartis Ag Application of 40-O-(2-hydroxyethyl)-rapamycin for treatment of solid kidney tumors
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
JP2005525345A (en) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Methods for treating TRX-mediated diseases
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
EP2082737B1 (en) * 2002-03-04 2014-12-31 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
MXPA04010199A (en) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Combination therapy for the treatment of cancer.
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US20070060615A1 (en) * 2003-02-18 2007-03-15 University Of South Florida Method of Modulating Apoptosis Through Modulation of E2F1
GB0315259D0 (en) * 2003-06-30 2003-08-06 Cyclacel Ltd Use
EP1663194B1 (en) * 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
WO2005023179A2 (en) * 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
EP1680123A1 (en) * 2003-11-06 2006-07-19 Cyclacel Limited Use
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
EP1942907A2 (en) * 2005-11-04 2008-07-16 Merck and Co., Inc. Methods of using saha and erlotinib for treating cancer
WO2007056135A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Method of treating cancers with saha and pemetrexed
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
WO2007054725A2 (en) * 2005-11-11 2007-05-18 Cyclacel Limited Combination of a cdk-inhibitor and a hdac-inhibitor
WO2008057456A2 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
US9156792B2 (en) * 2008-05-09 2015-10-13 University Of Maryland, Baltimore Retinamide and uses thereof
US20130005747A1 (en) * 2010-12-21 2013-01-03 Cyclacel Limited Method for selecting a cancer therapy
MX2018006250A (en) 2015-11-18 2018-09-05 Genzyme Corp Biomarker of polycystic kidney disease and uses thereof.
CN109803684B (en) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 Combination therapy for the treatment of hepatocellular carcinoma
JP7219224B2 (en) 2017-03-16 2023-02-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combination therapy for the treatment of breast cancer
JP7136807B2 (en) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ Polymeric materials for the intestinal delivery of short-chain fatty acids for therapeutic applications in human health and disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880152A (en) * 1995-10-06 1999-03-09 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
WO1997034598A1 (en) * 1996-03-20 1997-09-25 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating cancer using c-26 modified bryostatin
US6211239B1 (en) * 1996-07-17 2001-04-03 Centre International De Recherches Dermatologiques Galderma Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
US6034074A (en) * 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US5922571A (en) * 1997-03-06 1999-07-13 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein kinase C homolog
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
US20020016293A1 (en) * 2000-04-21 2002-02-07 Ratain Mark J. Flavopiridol drug combinations and methods with reduced side effects

Also Published As

Publication number Publication date
WO2002022133A1 (en) 2002-03-21
US20050004007A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
AU2001287157A1 (en) Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
AU2728201A (en) 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
AU2001278070A1 (en) Basal cell markers in breast cancer and uses thereof
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
IL151045A0 (en) 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
AU2003284242A1 (en) Methods and compositions for use in treating cancer
AU2002227300A1 (en) Reducing cellular damage in the human body
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU2003256410A1 (en) COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
AU2003298937A1 (en) Heterocyclic compounds, methods of making them and their use in therapy
AU1453301A (en) Methods of reversing drug resistance in cancer cells
HK1048820A1 (en) Compositions and methods for double-targeting virus infections and targeting cancer cells
AU2001258381A1 (en) Use of parp inhibitors in cosmetic preparations
AU2002256347A1 (en) Compositions and methods for the identification of protein interactions in vertebrate cells
AU2002356898A1 (en) Gene amplification and overexpression in cancer
AU4642600A (en) Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells
AU2000237154A1 (en) Method for detecting and killing epithelial cancer cells
AU2003217649A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING NF-KappaB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS
AU2003257043A1 (en) Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
AU2899800A (en) Compounds and methods for stimulating gene expression and cellular differentiation
HK1048599A1 (en) Cancer cell implantation inhibitors
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU2001288219A1 (en) Stimulation of cellular regeneration and differentiation in the inner ear
EP1575512A3 (en) Methods and compositions for prostate epithelial cell differentiation